Skip to main content
DeprescribingBehavioralBehavioral

What this study is

We will use EHR data to identify eligible patients at BWH primary care clinics. Patients will be eligible if they have an upcoming primary care provider (PCP) appointment at an included BWH clinic, are ≥65 years, and are eligible for a medication target; exclusion criteria will include relevant EHR-documented allergies. After sharing patients with PCPs for potential opt-out, patients will be randomized 1:1 in REDCap® to intervention or usual care (no prompt). The intervention will include a pre-visit patient-facing prompt with information about the evidence-based medication target. If patients are eligible for multiple targets, one will be randomly selected. The primary clinical outcome will be measured on the day of the PCP visit using EHR data, depending on target: a) discontinuation or tapering order, or b) prescribing. Secondary outcomes will include a) these same measures in a 60-day follow-up period after the visit to capture any follow-up actions. We will use an intention-to-treat approach including patients regardless of whether the visit occurred. We plan to conduct the trial until 1700 patients are reached. We will also conduct exploratory mediation analyses of mechanisms through brief patient surveys with behavioral scales and PCP survey.

What's being tested

  • Pre-visit prompts

    Intervention · BEHAVIORAL

    The intervention itself is a pre-visit prompt delivered prior to upcoming visits that includes a brief recommendation to the patient to discuss the medication use target with the PCP at the visit and a handout about the medication. The medication targets include potentially-inappropriate medications and statin prescribing.

Study details

Official title
Testing the Impact of Pre-visit Priming as a Mechanism Across Multiple Medication Use Behavioral Targets in Primary Care Practice
Sponsor
Brigham and Women's Hospital
Conditions
Deprescribing · Statin Prescribing
Enrolling
1,700 people
Starts
2026-06-10
Est. completion
2027-02-15
Design
Double-blind, randomized, parallel groups
Record
View on ClinicalTrials.gov ↗